Company news

Lipocine Inc. news in 2026

Lipocine Inc.'s news releases, calls and decks from 2026, newest first.

View company

Lipocine Announces Financial Results for the Third Quarter of 2026

November 5, 2026

Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy

October 7, 2026

Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression

September 14, 2026

Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 10, 2026

Lipocine Appoints Michael J. Grissinger to Board of Directors

August 3, 2026

Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154

June 3, 2026

Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting

May 18, 2026

Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase

May 18, 2026

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026

May 7, 2026

Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression

April 1, 2026

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

March 9, 2026

Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)

February 18, 2026

Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

January 20, 2026

Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

January 12, 2026

Decks in 2026